BioSpace News Archive

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today provided a business update and reported financial results for the second quarter ended June 30, 2022.

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and operating results after market close on Thursday, August 4, 2022.

Guardant Health, Inc., a leading precision oncology company, announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program, has conveyed coverage for the Guardant Reveal™ molecular residual disease test.

Twist Bioscience Corporation today shared a new white paper from Furthur Market Research1 highlighting the dramatic need for new enterprise storage technologies that can be deployed more cost effectively at massive scale with minimal power consumption, such as DNA data storage.

Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8009, an antibody drug conjugate (ADC) that targets B7-H3 (CD276).

IVERIC bio, Inc. reported that on August 1, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.

Infinity Pharmaceuticals, Inc . will host a conference call on Tuesday, August 9th , 2022, at 4:30 pm ET to report its financial results for the second quarter of 2022.

Agilent Technologies Inc. (NYSE: A) today announced it has acquired Polymer Standards Service GmbH (PSS), a provider of solutions in the field of polymer characterization. PSS specializes in hardware and software solutions used in defining the makeup and creation of molecular structures.

Peptilogics will participate in the Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting taking place in Pittsburgh August 5-6.

InterVenn® Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced the start of enrollment in its prospective cohort study for early detection of colorectal cancer and adenomas.